Status:
COMPLETED
Combination Of PAXIL Tablet And Benzodiazepines
Lead Sponsor:
GlaxoSmithKline
Conditions:
Mental Disorders
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive ep...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with depression or depressive episodes who are diagnosed to have major depressive disorders according to the DSM-IV criteria.
- Patients with 14 or higher points in total scores for Items No.1 - 17 on HAM-D.
- Patients who have continuously received Benzodiazepine anxiolytics.
- Exclusion criteria:
- Patients with a strong suicide tendency.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00259883
Start Date
June 1 2005
End Date
February 1 2006
Last Update
January 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site